Profile data is unavailable for this security.
About the company
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
- Revenue in USD (TTM)0.00
- Net income in USD-24.92m
- Incorporated2021
- Employees41.00
- LocationCalidi Biotherapeutics Inc4475 Executive Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 794-9600
- Fax+1 (858) 794-9605
- Websitehttps://www.calidibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TFF Pharmaceuticals Inc | 1.20m | -19.39m | 8.01m | 19.00 | -- | 1.28 | -- | 6.66 | -7.95 | -7.95 | 0.4659 | 1.81 | 0.1043 | -- | 3.51 | 63,293.68 | -168.10 | -79.57 | -212.66 | -83.41 | -- | -- | -1,612.04 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Correlate Energy Corp | 5.65m | -34.51m | 8.02m | 19.00 | -- | -- | -- | 1.42 | -0.8359 | -0.8359 | 0.1457 | -0.0461 | 1.50 | -- | 11.12 | 297,377.40 | -915.61 | -315.47 | -- | -- | -6.45 | 15.42 | -610.79 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Cell MedX Corp | 0.00 | -142.49k | 8.03m | 0.00 | -- | -- | -- | -- | -0.0021 | -0.0021 | 0.00 | -0.0028 | 0.00 | -- | -- | -- | -190.76 | -703.78 | -- | -- | -- | 84.03 | -- | -2,996.54 | -- | -4.35 | -- | -- | -100.00 | -- | 71.22 | -- | -- | -- |
| Vitro Biopharma Inc | 2.11m | -10.44m | 8.05m | 10.00 | -- | -- | -- | 3.82 | -2.35 | -2.35 | 0.4745 | -1.69 | 0.2765 | 1.71 | 20.61 | 210,873.00 | -136.91 | -- | -1,046.98 | -- | 83.48 | -- | -495.08 | -- | 0.1865 | -4.19 | -- | -- | -46.45 | -- | 31.01 | -- | -- | -- |
| Nascent Biotech Inc | 0.00 | -1.92m | 8.08m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -32.06m | 8.27m | 80.00 | -- | -- | -- | -- | -2.91 | -2.91 | 0.00 | -0.2384 | 0.00 | -- | -- | 0.00 | -170.53 | -70.02 | -727.24 | -79.98 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
| Silexion Therapeutics Corp | 0.00 | -523.87k | 8.50m | 0.00 | -- | 1.33 | -- | -- | -0.1403 | -0.1403 | 0.00 | 0.6559 | 0.00 | -- | -- | -- | -3.13 | -- | -3.77 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.96 | -- | -- | -- |
| Carmell Corp | 12.32k | -15.97m | 8.60m | 9.00 | -- | -- | -- | 698.09 | -1.53 | -1.44 | 0.0006 | -0.0656 | -- | -- | -- | 1,368.89 | -- | -- | -- | -- | 58.73 | -- | -129,263.60 | -- | 0.6901 | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
| ABVC Biopharma Inc | 136.40k | -11.37m | 8.64m | 16.00 | -- | 1.01 | -- | 63.36 | -1.78 | -1.78 | 0.0172 | 0.6882 | 0.0114 | -- | 0.4213 | 8,525.00 | -99.79 | -103.38 | -197.79 | -231.54 | -24.11 | 76.25 | -8,762.13 | -2,019.89 | -- | -2.50 | 0.1873 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Soligenix Inc | 494.62k | -7.04m | 8.71m | 13.00 | -- | 1.70 | -- | 17.61 | -9.58 | -9.58 | 0.6152 | 2.25 | 0.0418 | -- | 8.70 | 38,047.69 | -59.45 | -75.40 | -121.64 | -154.32 | 8.75 | 22.83 | -1,423.81 | -620.02 | -- | -- | 0.4421 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -24.92m | 8.81m | 41.00 | -- | -- | -- | -- | -5.41 | -5.41 | 0.00 | -1.82 | 0.00 | -- | -- | 0.00 | -279.89 | -- | -- | -- | -- | -- | -- | -- | -- | -27.58 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -45.34m | 8.82m | 40.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | 0.0678 | 0.00 | -- | -- | 0.00 | -83.82 | -86.35 | -140.98 | -106.38 | -- | -- | -- | -11,853.94 | -- | -59.78 | 0.8753 | -- | -- | -- | -3.78 | -- | -- | -- |
| Molecular Templates Inc | 25.47m | -15.63m | 8.89m | 62.00 | -- | 1.25 | -- | 0.349 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| BioCardia Inc | 428.00k | -8.56m | 8.89m | 16.00 | -- | -- | -- | 20.78 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Inhibikase Therapeutics Inc | 79.57k | -18.38m | 8.96m | 8.00 | -- | 1.70 | -- | 112.57 | -2.93 | -2.93 | 0.0126 | 0.7063 | 0.0051 | -- | -- | 9,946.25 | -117.93 | -66.49 | -148.63 | -85.55 | -- | -- | -23,102.16 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Portage Biotech Inc | 0.00 | -71.08m | 9.15m | 7.00 | -- | 3.64 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
Data as of Sep 21 2024. Currency figures normalised to Calidi Biotherapeutics Inc's reporting currency: US Dollar USD
13.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cable Car Capital LLCas of 04 Sep 2024 | 897.24k | 11.10% |
| Red Wave Investments LLCas of 30 Jun 2024 | 62.46k | 0.77% |
| CPR Investments, Inc.as of 30 Jun 2024 | 56.00k | 0.69% |
| R.S. Crum, Inc.as of 30 Jun 2024 | 26.35k | 0.33% |
| Delta Investment Management LLCas of 30 Jun 2024 | 21.02k | 0.26% |
| Citadel Securities LLCas of 30 Jun 2024 | 12.59k | 0.16% |
| Finepoint Capital LPas of 30 Jun 2024 | 12.50k | 0.16% |
| Polar Asset Management Partners, Inc.as of 30 Jun 2024 | 12.50k | 0.16% |
| HRT Financial LLCas of 30 Jun 2024 | 10.14k | 0.13% |
| Driehaus Capital Management LLCas of 30 Jun 2024 | 9.47k | 0.12% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
